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cost-effective situation was maintained in all sensitivity analyses. In deterministic 
analysis, the results were most sensitive to differences in index hospitalisation length 
of stay between strategies and proportional GPI utilisation (eptiﬁbatide/abciximab). 
In probabilistic analysis, 95.6% of samples (9,557 of 10,000) indicated a dominant 
situation. CONCLUSIONS: The use of bivalirudin instead of heparin plus GPI 
is dominant, i.e. clinically advantageous and cost-saving, in STEMI patients planned 
for PPCI, when UK valuations are applied to the HORIZONS study.
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OBJECTIVES: Pulmonary Arterial Hypertension (PAH) is a devastating disease, 
which has a signiﬁcant impact on patients’ quality of life and mortality. Both bosentan 
and inhaled iloprost (INHI) have demonstrated prolonged survival in long-term obser-
vational studies. We assessed the cost-effectiveness of adding bosentan, INHI or no 
active treatment (NAT) to palliative care, for patients with PAH of functional class 
(FC) III in Finland. METHODS: A cost-utility model simulated hypothetical patients 
with PAH, using a lifetime horizon and considering only direct medical costs. Patients 
were assumed to either remain in their FC at 12 weeks until death or to deteriorate 
to FC IV and then receive INHI and palliative care until death. It was assumed that 
the initial choice of treatment would not affect survival, but instead would affect the 
proportion of time spent in FC IV. Deterioration was approximated by time to clinical 
worsening (TTCW), a composite measure of death or worsening of PAH leading to a 
change in treatment. Data on TTCW was taken from published literature and hospital 
databases containing over three years of data for bosentan and from published litera-
ture for palliative care alone. For INHI, the TTCW was favourably assumed to equal 
that for bosentan. The utility associated with each FC taken from published literature; 
non-drug costs were estimated based on published literature and veriﬁed by a Finnish 
expert clinician. Costs and beneﬁts were discounted at 3% per annum. RESULTS: 
Bosentan dominated INHI, providing equivalent QALYs at a reduced cost. Bosentan 
also dominated NAT, providing an additional 0.38 QALYs whilst saving a8.142. 
Probabilistic sensitivity analyses estimated the probabilities of bosentan being cost-
effective compared with NAT as 79% and 86% at cost per QALY thresholds of 
a30,000 and a50,000 respectively. CONCLUSIONS: Bosentan is a more cost-effective 
ﬁrst-line therapy for patients with PAH FC III in Finland than either INHI or NAT.
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OBJECTIVES: Primary Pulmonary Hypertension (PPH) is a rare, progressive degen-
erative disorder resulting in deteriorating functional status, poor quality of life and 
ultimately death. Inhaled iloprost is indicated for the treatment of patients with PPH 
at New York Heart Association (NYHA) functional class III. This study used an eco-
nomic model to evaluate the cost-effectiveness of inhaled iloprost compared to current 
standard treatment in PPH. METHODS: A Markov model was used to allocate 
patients to states according to NYHA functional classiﬁcation and treatment received. 
Patients enter the model when oral therapies have failed or not been tolerated and can 
improve NYHA classiﬁcation, remain stable, deteriorate or die. The model compares 
i) inhaled iloprost until patients reach NYHA IV; then, intravenous epoprostenol with 
ii) immediate epoprostenol. Efﬁcacy was taken from 12 week placebo controlled 
studies of each agent; quality of life from EQ-5D data collected in the study of iloprost. 
Costs were estimated at 2008 prices from the perspective of the NHS. The time horizon 
of the economic analysis is from failure of oral therapy until death; the primary 
outcome is cost per QALY gained. RESULTS: The model estimated that treating with 
inhaled iloprost will reduce lifetime cost by £348,000 (95% CI: £223,000, £529,000) 
and increase QALYs by 0.04 (0.92, 0.51) per person treated. The model is sensitive 
to the cost of the drugs used, but less sensitive to the other costs of managing PPH, 
utility inputs or the sources of efﬁcacy and safety inputs chosen. CONCLUSIONS: 
Using inhaled iloprost before epoprostenol offers substantial savings compared to 
immediate epoprostenol, with no signiﬁcant impact on health outcomes. The strategy          
of reserving intravenous therapy for patients unable to tolerate less expensive and 
invasive therapies would be economically attractive.
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OBJECTIVES: To estimate the long- and short-term costs and effects of 2 year treat-
ment with high-dose atorvastatin versus high and standard dose simvastatin in patients 
with acute coronary syndrome (ACS). METHODS: Efﬁcacy is estimated based on a 
Bayesian meta-analysis linking decrease in LDL cholesterol levels to decreases in sec-
ondary cardiac events (MIs, strokes, cardiovascular deaths) drawing data from statin 
trials in ACS (AtoZ, MIRACL, PROVE-IT) and using priors from published statin 
meta analyses (CTT, Law). A Markov model combines estimates of the occurrence of 
later events; Dutch cost data; and quality of life. Risks are taken from the ACS CURE 
study. RESULTS: Analyses are conducted using a baseline event risk during the ﬁrst 
6 months of 12.1% and of 3.89% during later months. A base case analysis of atorv-
astatin 80 mg versus simvastatin 80 mg is chosen to align with clinical trial evidence 
used in the Bayesian analysis. This resulted in a cost per QALY of a29,000 and a 
number needed to treat to avoid one event (NNT) estimate of 80. The comparison of 
atorvastatin 80 mg and simvastatin 40 mg resulted in a NNT of approximately 58 
and a cost per QALY estimate of a21,000, based on the assumption that atorvastatin 
80 mg has an 18% greater efﬁcacy in terms of LDL-C reduction. ICERs improve when 
risk with age is reduced, lower discount rates are used, and when atorvastatin cost is 
decreased. CONCLUSIONS: Based on preliminary ﬁndings, the probability that high-
dose atorvastatin has a cost effectiveness ratio under a30,000 is estimated at 67.3% 
when compared to simvastatin 40 mg and at 56.9% when compared with 80 mg of 
simvastatin. Univariate sensitivity analyses show that changes in the costs of atorvas-
tatin, and the risk of having events have the biggest impact on the results.
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OBJECTIVES: Dronedarone is a new multichannel-blocking antiarrhythmic drug. In 
ATHENA, dronedarone (400 mg bid), reduced cardiovascular hospitalizations or 
death by 24% (p  0.0001) versus standard of care (SOC) alone. Our objective was 
to predict the long-term health effects in terms of survival and quality-adjusted survival 
comparing dronedarone on top of SOC versus SOC alone, amiodarone or sotalol. 
METHODS: A state transition model (evaluated using 1st order Monte Carlo simula-
tion) was developed. When treated with dronedarone or SOC, the risk of suffering 
symptomatic AF, stroke, acute coronary syndromes (ACS), congestive heart failure or 
cardiovascular death, or discontinuing treatment was estimated using survival analysis 
based on the ATHENA patient level data (n  4,628). Death from non-cardiovascular 
causes or following stroke or CHF was based on UK national statistics and literature 
data. Patients treated with amiodarone or sotalol had the risk of events modiﬁed with 
relative risks based on a mixed treatment comparison. When discontinuing dronedar-
one or rhythm control therapy, patients were assumed to receive SOC alone and thus 
have the same transition probabilities as in the SOC arm. Outcomes were discounted 
at 3.5% per annum. RESULTS: Assuming lifetime treatment, the predicted survival 
with dronedarone was 9.01. The corresponding number of QALYs was 6.97. With 
amiodarone, the model predicts an expected survival of 7.14 years (5.52 QALYs). For 
sotalol the corresponding numbers were 5.83 years and 4.53 QALYs. CONCLU-
SIONS: Dronedarone demonstrated longer predicted survival compared to SOC alone, 
amiodarone and sotalol. This beneﬁt is sustained when adjusted by quality of life, and 
is comparable with survival gains from established interventions in cardiology.
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OBJECTIVES: Preliminary evidence indicates that intra-arterial (IA) thrombolysis is 
a more effective treatment for a subgroup of ischemic stroke patients who have a 
visible intracranial occlusion than intravenous (IV) thrombolysis. This cost-utility 
analysis compares four treatment strategies for ischemic stroke: conservative treat-
ment, IV thrombolysis, IA thrombolysis and a bridging strategy of both IV and IA 
thrombolysis (with or without mechanical thrombectomy). METHODS: A health 
economic model was developed that compared the four different treatments. A deci-
sion tree with a Markov model was used to assess 6 months- and lifetime costs (in 
Euros) and effects (in QALYs) of these different treatment strategies. A literature 
search provided the estimates used in the decision tree and data from the EDISSE trial 
was used for cost estimates, combined with cost estimates from Erasmus MC Univer-
sity Hospital Rotterdam on IA thrombolysis. Current Dutch epidemiological informa-
tion was used in the Markov model to calculate lifetime costs and effects for all 
treatment strategies. RESULTS: From a lifetime perspective, IV thrombolysis is the 
dominant treatment strategy: it saves a1717 per QALY gained compared to the con-
servative treatment. The bridging strategy costs an additional a7217 per QALY gained 
compared to IV thrombolysis. IA thrombolysis is dominated by the other strategies 
as it gains equal QALYs as IV thrombolysis while it is a slightly more expensive treat-
ment. A probabilistic sensitivity analysis shows that depending on the willingness to 
pay, these treatment strategies are cost-effective at six months in 84 percent of cases. 
CONCLUSIONS: The bridging strategy signiﬁcantly improves functional outcome of 
acute ischemic stroke patients at reasonable additional costs. However, more empirical 
studies need to be performed in order to reduce the considerable amount of uncertainty 
concerning the costs and effects of IA thrombolysis for acute ischemic stroke.
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OBJECTIVES: The aim of our study was to compare the costs and cost drivers of 
contrast-enhanced magnetic resonance angiography (MRA) and digital subtraction 
